MADISON, Wis. (SPECTRUM NEWS) -- The University of Wisconsin School of Medicine and Public Health and UW Health announced on Tuesday that, along with Regeneron Pharmaceuticals, a series of clinical trials of a potential COVID-19 vaccine will now take place in Wisconsin.

Dubbed REGN-COV2, a press release issued Tuesday indicates that the New York-based pharmaceutical company's "scientists selected virus-neutralizing antibodies produced from mice that have been genetically modified to simulate a human immune system, as well as antibodies identified from humans who have recovered from COVID-19..."

Dr. William Hartman, assistant professor of anesthesiology at the UW School of Medicine and Public Health, will lead the series of clinical trials in Wisconsin.

"There are actually three trials that will go on simultaneously," Dr. Hartman told Spectrum News 1. "[It's] two different antibodies, non-competing antibodies-- "the biggest hitters" that they've found when looking at an animal model and convalescent plasma-- these two antibodies, instead of putting the whole team on the court as you would with convalescent plasma, it's sending out Michael Jordan and Scottie Pippen and all their clones to go out and attack that virus."

Tuesday's statement from the University of Wisconsin School of Medicine and Public Health went on to say that '[t]he experimental antibodies interact with the receptor binding domain of the COVID-19 virus’s spike protein and block viral interaction with human angiotensin-converting enzyme 2, or ACE2, which is the protein the virus docks with during infection."

You can see the entire interview with Dr. Hartman above.